Omeprazol Healthkern (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Healthkern, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related disorders in adults and children. GNH USA supplies Omeprazol Healthkern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Healthkern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway.

- Gastro‑oesophageal reflux disease (GERD): provides relief from heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: facilitates ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced ulcer prophylaxis: lowers risk of ulcer development in patients regularly using non‑steroidal anti‑inflammatory drugs.

Adverse reactions to omeprazole are generally mild and dose‑dependent.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output. - Hypomagnesemia: low magnesium levels causing muscle cramps or cardiac arrhythmia. - Stevens‑Johnson syndrome: rare skin and mucous membrane disorder. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Fracture risk: potential reduction in bone mineral density with long‑term use.

When using Omeprazol Healthkern, consider the following precautions:

- Assess renal function: adjust use in patients with severe kidney impairment. - Evaluate hepatic status: use cautiously in liver disease. - Review long‑term therapy: monitor for osteoporosis and fractures. - Pregnancy and lactation: weigh benefits against potential risks. - Drug interactions: check concomitant medications for possible effects. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, compromising HIV therapy effectiveness. - Methotrexate: increased serum levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring more frequent monitoring. - Digoxin: possible increase in serum concentration. - Phenytoin: reduced plasma concentration, may diminish seizure control. - Ketoconazole: decreased absorption, lowering antifungal efficacy.